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Abstract. 
 
It has been proposed that the urokinase re-
ceptor (u-PAR) is essential for the various biological 
roles of urokinase-type plasminogen activator (u-PA) 
in vivo, and that smooth muscle cells require u-PA for 
migration during arterial neointima formation. The 
present study was undertaken to evaluate the role of 
u-PAR during this process in mice with targeted disrup-
tion of the 
 
u-PAR
 
 gene (u-PAR
 
2
 
/
 
2
 
). Surprisingly, 
u-PAR deficiency did not affect arterial neointima for-
mation, neointimal cell accumulation, or migration of 
smooth muscle cells. Indeed, topographic analysis of ar-
terial wound healing after electric injury revealed that 
u-PAR
 
2
 
/
 
2
 
 smooth muscle cells, originating from the 
uninjured borders, migrated over a similar distance and 
at a similar rate into the necrotic center of the wound as 
wild-type (u-PAR
 
1
 
/
 
1
 
) smooth muscle cells. In addition, 
u-PAR deficiency did not impair migration of wounded 
cultured smooth muscle cells in vitro. There were no 
genotypic differences in reendothelialization of the vas-
cular wound. The minimal role of u-PAR in smooth 
muscle cell migration was not because of absent expres-
sion, since wild-type smooth muscle cells expressed 
 
u-PAR
 
 mRNA and functional receptor in vitro and in 
vivo. Pericellular plasmin proteolysis, evaluated by deg-
radation of 
 
125
 
I-labeled fibrin and activation of zy-
mogen matrix metalloproteinases, was similar for 
u-PAR
 
2
 
/
 
2
 
 and u-PAR
 
1
 
/
 
1
 
 cells. Immunoelectron mi-
croscopy of injured arteries in vivo revealed that u-PA 
was bound on the cell surface of u-PAR
 
1
 
/
 
1
 
 cells, whereas 
it was present in the pericellular space around u-PAR
 
2
 
/
 
2
 
 
cells. Taken together, these results suggest that binding 
of u-PA to u-PAR is not required to provide sufficient 
pericellular u-PA–mediated plasmin proteolysis to al-
low cellular migration into a vascular wound.
 
F
 
ormation 
 
of blood vessels during embryogenesis in-
volves proliferation and migration of endothelial
and smooth muscle cells. During adulthood, these
vascular cell types differentiate, are quiescent, and have a
prolonged lifetime. However, after arterial injury such as
during vascular interventions for the treatment of athero-
thrombosis in patients, smooth muscle cells of the medial
layer accumulate into the intima and endothelial cells mi-
grate into denuded wounds (15). Since smooth muscle
cells are “encaged” by a basement membrane, they need
to proteolytically degrade extracellular matrix components
to migrate to distant sites. Another cell type frequently
present in the injured vessel wall is the leukocyte, which
participates in removal of necrotic material, orchestrating
the inflammatory response, and assisting migration of
other cells by clearing a path for them (31). Smooth mus-
cle cells, endothelial cells, and leukocytes produce a vari-
ety of matrix-degrading proteinases, of which the plasmin-
ogen system and the matrix metalloproteinase system are
generally believed to play an essential role in cellular mi-
gration; because they can, in concert, break down all dif-
ferent matrix components of the vessel wall (7, 24, 30, 56).
Matrix metalloproteinases (MMPs)
 
1
 
 constitute a family
of proteinases able to degrade most extracellular matrix
components in the vessel wall. In the mouse, MMP-13
(collagenase 3) appears to be the primary interstitial colla-
genase, whereas MMP-2 (gelatinase A) and MMP-9 (gela-
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tinase B) degrade collagen type IV, V, VII, and X, elastin,
and denatured collagens (40). Since MMPs are secreted as
zymogens, they require extracellular activation. We re-
cently demonstrated that urokinase-type plasminogen ac-
tivator (u-PA)–generated plasmin is a likely pathological
activator of several zymogen MMPs during atherosclerotic
aneurysm formation in vivo (11). Increased levels of ma-
trix metalloproteinases have been proposed to mediate
cellular migration and vessel wall remodeling during arte-
rial intimal thickening (3, 24).
The plasminogen system comprises two plasminogen ac-
tivators (PAs), tissue-type PA (t-PA), and urokinase-type
PA (u-PA), which convert the proenzyme plasminogen to
its active derivative, plasmin (17). They are controlled by
plasminogen activator inhibitors (PAIs), of which PAI-1
appears to be the predominant physiological inhibitor.
Whereas t-PA is primarily involved in clot dissolution, u-PA
binds to a membrane-anchored glycoprotein (u-PAR/
CD87), which has been implicated in pericellular proteoly-
sis during cell migration or tissue remodeling (2, 4, 8, 57).
It has been claimed that binding of u-PA to u-PAR is re-
quired for its role in pericellular proteolysis because it would
accelerate plasminogen activation, delay inhibition by PAI-1,
regulate clearance of u-PA, and localize plasmin proteoly-
sis to the cell surface at the leading edge of the migrating
cell (2, 4, 27, 57). Recent studies suggest that u-PAR may
be a multifunctional receptor, not only promoting pericel-
lular proteolysis but also involved in integrin-mediated
cell adhesion and migration via interaction with vitronec-
tin (22, 28, 58, 59, 64) or the complement receptor type-3/
Mac-1 receptor (CD11b/CD18) (53, 61, 63). In addition,
u-PAR has been implicated in intracellular signaling, cel-
lular differentiation, growth, and chemotaxis via a mecha-
nism independent of the enzymatic activity of u-PA but
dependent on receptor occupancy (1, 20, 28, 43, 44, 46, 58).
Although expression and manipulation of 
 
u-PAR
 
 gene
function have been directly correlated with cellular migra-
tion in vitro, and with primary tumor growth, tumor-asso-
ciated neovascularization and metastasis in vivo (18, 19,
38, 42, 50, 62, 66), it remains to be determined whether
receptor binding of u-PA is required during other (patho)
biological processes in vivo. In fact, binding of u-PA to
u-PAR may not be always necessary since a membrane-
anchored form of u-PA catalyzes plasminogen activation
equally well as receptor-bound u-PA (29), and inhibition
(60) or overexpression (65) of soluble u-PA also alters cel-
lular invasiveness. In addition, loss of 
 
u-PAR
 
 gene func-
tion does not cause appreciable morphological or func-
tional defects in gene-inactivated mice in vivo (5, 6, 23).
Indeed, in contrast to the markedly impaired fibrin sur-
veillance and poor general health in combined t-PA/u-PA
deficient mice, mice with combined t-PA/u-PAR defi-
ciency display only minimal fibrin deposits and a normal
lifespan (6).
In an uninjured artery, endothelial cell–produced t-PA
may promote vascular patency. After injury, expression of
t-PA, u-PA, and u-PAR by smooth muscle cells, endothe-
lial cells, and leukocytes is significantly induced (16, 41,
45); and despite induced PAI-1 expression, a significant
hyperfibrinolytic response occurs. We recently demon-
strated, using a perivascular electric injury model (14),
that deficiency of plasminogen or u-PA but not of t-PA, or
adenoviral 
 
PAI-1
 
 gene transfer, suppresses arterial wound
healing because of impaired migration of smooth muscle
cells, whereas deficiency of PAI-1 enhances this process
(9, 12, 13).
In the present study, the role of u-PAR in arterial
wound healing was studied in mice with an inactivated gene
encoding u-PAR (u-PAR
 
2
 
/
 
2
 
). The dependence of cellular
migration during arterial wound healing on u-PA–medi-
ated plasmin proteolysis (9, 13), allowed us to examine
whether binding of u-PA to u-PAR is essential for its role
in controlling directional plasmin proteolysis. Surprisingly,
neointima formation and smooth muscle cell migration
were not impaired by deficiency of u-PAR, indicating that
u-PAR is not essential for the biological role of u-PA in
vascular wound healing. In fact, the present analysis sug-
gests that pericellular u-PA around vascular cells induces
sufficient pericellular plasmin and MMP proteolysis to al-
low normal cellular migration. These findings may have
implications for the design of therapeutic strategies to re-
duce u-PA–mediated arterial stenosis.
 
Materials and Methods
 
Arterial Injury Model, Morphometric Analysis, 
Histology and Immunocytochemistry
 
6–8-wk-old u-PAR
 
1
 
/
 
1
 
 and u-PAR
 
2
 
/
 
2
 
 mice (23) of either sex with a mixed
C57Bl6 
 
3
 
 129/SvPas genetic background were used. Groups of 8–14 ani-
mals were studied. Perivascular electric injury of left femoral arteries and
analysis of neointima (morphometric measurements of cross-sectional ar-
eas, cell counts, and proliferation rates, reendothelialization, topographic
analysis, and immunostainings) were performed as described elsewhere
(14). t-PA, u-PA, and PAI-1, or MMP-9 and MMP-13 were immuno-
stained as described, except that cultured cells were pretreated for 24 h
with monensin (1 
 
m
 
M; Sigma Chemical Co., St. Louis, MO) (9, 14).
 
Smooth Muscle Cell Cultures and In Vitro
Migration Assay
 
Smooth muscle cells were prepared (9) and wound assays were performed
in vitro (49) as described. Briefly, smooth muscle cells were seeded in DME
containing 10% FCS onto 35-mm dishes, precoated with human fibronec-
tin (5 
 
m
 
g/ml during 24 h at 4
 
8
 
C) to prevent retraction of wounded smooth
muscle cells. After 7 d, confluent smooth muscle cells were wounded with
a razor blade, washed with PBS, and further incubated for 72 h at 37
 
8
 
C in
DME containing 0.1% gelatin and 10% FCS. After fixation with absolute
methanol, the cells were stained with Giemsa. Cells that had migrated
from the edge of the wound into the denuded area were counted in seven
successive 125-
 
m
 
m increments at 
 
3
 
100 magnification.
 
In Situ Hybridization and Electron Microscopy
 
In situ hybridization was performed using a 1,113-nucleotide human 
 
u-PAR
 
,
or a 159-nucleotide murine 
 
u-PAR
 
 
 
35
 
S-labeled riboprobe, with similar re-
sults (35). Ultrastructural analysis was performed as described (33). For
immunogold labeling, the tissues were perfusion fixed for 10 min, fol-
lowed by immersion fixation at room temperature for a further 2 h using
3% formaldehyde in PBS. Thereafter, the samples were dehydrated with
increasing concentrations of ethanol at progressively lower temperatures.
Finally, the samples were embedded overnight in 100% Lowicryl K4M at
 
2
 
35
 
8
 
C. Polymerization was carried out by irradation of tissue in gelatin
capsules by indirect UV light for 24 h at 
 
2
 
35
 
8
 
C, followed by final harden-
ing under UV light at room temperature for 1–2 d. The thin sections were
placed on Formvar-coated 200-mesh nickel grids, and then immunogold
labeled for u-PA using a postembedding staining protocol as previously
described (34). A polyclonal rabbit anti-murine u-PA antiserum (10) or a
monoclonal anti-murine u-PA antibody (clone No. H77A10; 30 
 
m
 
g/ml) (9)
were used, with similar labeling characteristics. 
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Reverse Transcriptase (RT)-PCR Analysis
 
Expression of 
 
u-PAR
 
 mRNA was evaluated using RT-PCR analysis of to-
tal RNA prepared from cultured smooth muscle cells, uninjured arteries,
or arteries at the indicated periods after injury. Preparation of RNA, syn-
thesis of first strand cDNA and PCR amplification were carried out as
described (23). The following primers were used: 5
 
9
 
-CAGAGCTTTCC-
ACCGAATGGCTTCC-3
 
9
 
 sense; and 5
 
9
 
-CAGCAACAATATTATCTCA-
ACTAAGAGG-3
 
9
 
 and 5
 
9
 
-GAAACCGGAGTTATACCGTAAGAGGC-3
 
9
 
,
antisense.
 
Binding of 
 
125
 
I-Labeled u-PA to Cultured Smooth 
Muscle Cells
 
Binding of u-PA to smooth muscle cells was evaluated by iodination of a
recombinant murine u-PA polypeptide, containing the first 48 amino acid
residues (mu-PA
 
1–48)
 
 (38), as previously described (23). Smooth muscle
cells were plated at a density of 2 
 
3
 
 10
 
5
 
 cells per well in 96-well plates. Af-
ter overnight culture, the cells were acid-treated to dissociate endogenous
u-PA from u-PAR by adding 100 
 
m
 
l of a 50 mM glycine-HCl buffer, pH
3.0, containing 100 mM NaCl for 3 min, which was then neutralized by ad-
dition of 20 
 
m
 
l of 500 mM Hepes buffer, pH 7.5, containing 100 mM NaCl.
After a wash with binding medium (DME containing 0.1% sterile BSA),
the cells were incubated for 1 h at room temperature in 100 
 
m
 
l binding me-
dium containing 
 
125
 
I-labeled mu-PA
 
1–48
 
, with or without cold mu-PA
 
–48
 
 or
human u-PA at the indicated concentrations. After three washes, the cells
were lysed with 100 
 
m
 
l of 1 M NaOH, and the lysate counted for cell-asso-
ciated radioactivity. These values were corrected for background radioac-
tivity in the absence of cells. Cell loss was evaluated in separate wells,
treated in an identical manner as those used for counting of radioactivity.
 
In Situ Autoradiography of 
 
125
 
I–u-PA Binding
 
For in situ autoradiography, cultured smooth muscle cells were plated at a
density of 2–20 
 
3
 
 10
 
3
 
 cells per 8-well chamber of the Lab-Tek slides
(Chamber slides
 
TM
 
; Nunc Inc., Naperville, IL) and cultured overnight.
The cells were then washed, acid treated, and incubated in binding me-
dium containing 
 
125
 
I-labeled with or without cold mu-PA
 
1–48
 
 as described
above. After incubation, the cells were washed three times. For light mi-
croscopy, the cells were fixed with 2% glutaraldehyde in 0.1 M sodium-
cacodylate buffer, pH 7.6, for 1 h, washed three times for 10 min with cac-
odylate buffer, dried, dipped in photographic emulsion (LM-1 emulsion;
Amersham, Brussels, Belgium), and then developed after 3–14 d. For
electron microscopy, the cells were fixed with 2.5% glutaraldehyde in 0.1 M
HCl-sodium-cacodylate buffer, postfixed in 1% osmiumtetroxide in the
same buffer, dehydrated in graded ethanol series, and then embedded in
epoxy resin. Ultrathin sections were placed on Formvar-coated grids,
coated in the dark by dipping in Ilford L4 radioautographic emulsion (Il-
ford Ltd., Mobberley Knutsford, Cheshire, UK), exposed for 14 d, and
then developed in Kodak D19 and Kodak Ectaflow (Eastman Kodak,
Rochester, NY) fixer before examination.
 
Fibrin Zymography, Plasminogen Activation, and
 
125
 
I-Fibrin Degradation
 
Zymographic analysis of plasminogen activator activities in arterial ex-
tracts or cell-conditioned media (9, 13), in situ zymography of plasmino-
gen activators on 7-
 
m
 
m arterial cryosections (9), plasminogen activation
by cell-associated endogenous u-PA (in the presence of the chromogenic
plasmin substrate S2403) (23), 
 
125
 
I-fibrin degradation (9), and quantitation
of murine t-PA and u-PA antigen in cell-conditioned media by ELISA
(21) were performed as described.
 
Macrophage Cell Culture and Metalloproteinase Assays
 
Peritoneal macrophages were harvested 3–5 d after intraperitoneal injec-
tion of 0.5 ml 4% Brewers thioglycollate medium (Difco Laboratories
Inc., Detroit, MI) and cultured overnight with serum-free DME supple-
mented with 2 mM glutamine, 0.02% lactalbumine hydrolyzate, and 300 nM
phorbol myristate acetate (PMA). The following day, the cells were
starved with methionine/cysteine-free, serum-free DME supplemented with
2 mM glutamine, 0.02% lactalbumine hydrolyzate, and 300 nM PMA for
60 min, after which 100 
 
m
 
Ci/ml of 
 
35
 
S-labeled methionine/cysteine (Amer-
sham) and plasminogen (10 
 
m
 
g/ml final concentration as indicated) were
added. After 8 h, the conditioned medium was immunoprecipitated with
 
rabbit anti-murine MMP-9 or MMP-13 antibodies, and subjected to zymo-
graphic gelatin gel electrophoresis (MMP-9) or gel electrophoresis and
autoradiography (MMP-9, MMP-13) (11).
 
Statistical Analysis
 
Experimental values were expressed as the mean 
 
6
 
 SEM. Statistically sig-
nificant differences between groups were calculated by analysis of vari-
ance followed by Bonferroni correction.
 
Results
 
Vascular Wound Healing in u-PAR
 
1
 
/
 
1
 
 Mice
 
Electric injury denuded the endothelium and destroyed all
cells in the media (
 
,
 
1% surviving medial cells), resulting
in a wound healing response characterized by transient
thrombosis, removal of necrotic debris, reendothelializa-
tion, repopulation of the media by smooth muscle cells,
and the formation of a neointima with multiple layers of
smooth muscle cells within 3–4 wk after injury (Fig. 1 and
2, 
 
a
 
 and 
 
b
 
) (12). A neoadventitia developed that was rich
in leukocytes and fibroblastlike cells. Wound healing and
the associated arterial neointima formation, and reendo-
thelialization initiated at the uninjured borders with subse-
quent progression into the necrotic center.
Figure 1. Schematic representation of the wound healing re-
sponse to perivascular electric injury and the topographic pattern
of neointima formation in u-PAR1/1 and u-PAR2/2 arteries. The
media of an uninjured mouse femoral artery consists of two to
three layers of smooth muscle cells. There are no smooth muscle
cells in the intima. 2 d after injury, the injured segment in the me-
dia is depleted of smooth muscle cells. Within 1 wk after injury,
cells begin to repopulate the media and a small neointima is
formed at the borders of the injury. The insert shows the pre-
sumed migration of smooth muscle cells across the internal elastic
lamina, within the media, and alongside the lumen. Within 3–4
wk after injury, the media is repopulated and the neointima has
uniformly developed throughout the whole injured region. The
vertical lines below each artery denote the equally spaced loca-
tions that were used for the topographic analysis in Tables II, III
and Fig. 4. 
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Vascular Wound Healing in u-PAR
 
2
 
/
 
2
 
 Mice
 
After perivascular injury, removal of the necrotic debris,
repopulation of the media by smooth muscle cells, and ac-
cumulation of neointimal cells appeared to be not affected
by u-PAR deficiency, as evidenced by a normal neointima
at 3 wk after injury (Fig. 2 
 
c
 
). This was not anticipated
since deficiency of u-PA significantly impairs wound heal-
ing and arterial neointima formation (Fig. 2 
 
d
 
 displays a
representative example of impaired wound healing and re-
duced neointima formation in u-PA
 
2
 
/
 
2
 
 arteries, as previ-
ously reported [9]). Quantitative measurements of the
neointimal cross-sectional area (Fig. 3 
 
a
 
), the intima to
media ratio (Fig. 3 
 
b
 
), the percent luminal stenosis (Fig. 3
 
c
 
), and the number of neointimal cells (Fig. 3 
 
d
 
) revealed
that neointima formation in u-PAR
 
2
 
/
 
2
 
 mice was not statis-
tically different from that in u-PAR
 
1
 
/
 
1
 
 mice.
 
Proliferation of Smooth Muscle Cells
 
To evaluate whether deficiency of u-PAR affects cellular
proliferation, incorporation of 5
 
9
 
-bromo-2
 
9
 
-deoxyuridine
into replicating cells was determined (Table I). Prolifera-
tion of smooth muscle cells in electrically injured arteries
is best evaluated beyond 1 wk after injury, since the media
and neointima are then largely devoid of leukocytes (14).
As shown in Table I, medial and neointimal cell prolifera-
tion were not significantly different between u-PAR
 
1
 
/
 
1
 
and u-PAR
 
2
 
/
 
2
 
 arteries, except for an increased prolifera-
tion rate of u-PAR
 
2
 
/
 
2
 
 intimal smooth muscle cells within 2
wk after injury.
 
Migration of Smooth Muscle Cells
 
In Vivo Migration. 
 
After electric injury, smooth muscle
cells migrate within the media and alongside the lumen
from the uninjured borders into the center of the necrotic
wound (14). Progression of the neointima from the bor-
ders to the center was quantitated by measuring the lumi-
nal narrowing (percent stenosis) at equally spaced posi-
tions across the injured segment. Within 1 wk after injury,
a significant neointima was initiated at the borders of the
injury in both u-PAR
 
2
 
/
 
2
 
 arteries and in u-PAR
 
1
 
/
 
1
 
 arteries
(
 
P
 
 
 
5 NS versus u-PAR1/1 by analysis of variance) (Fig. 4
a). Within 3 wk after injury, the neointima had progressed
equally far into the center of the injury in u-PAR2/2 and in
u-PAR1/1 arteries (P 5 NS) (Fig. 4 b).
These findings were extended by counting the medial
and neointimal cell nuclei at the left border, center, and
right border of the injured segment (Fig. 1, locations 1, 5,
and 10 in the arteries), revealing that the cells migrated
over a similar distance and at a similar rate into the center
of the wound in u-PAR2/2 as in u-PAR1/1 arteries (Tables
II and III). This process is schematically represented in
Fig. 1. The lack of an effect of u-PAR deficiency on
smooth muscle cell migration in vivo contrasts with the im-
paired smooth muscle cell migration in mice lacking u-PA
or plasminogen (9, 13).
In vitro Migration. To confirm the lack of an effect of
u-PAR in smooth muscle cell migration, cultured smooth
muscle cells from wild-type and u-PAR2/2 mice were
wounded by scraping them from one part of the culture
dish and quantifying their accumulation into the denuded
area. Similar numbers of u-PAR1/1 smooth muscle cells
(165 6 12) and u-PAR2/2 smooth muscle cells (163 6 8;
P 5 NS) accumulated into the denuded area within 72 h.
However, migration of smooth muscle cells was dependent
on u-PA since only 35 6 2 u-PA2/2 smooth muscle cells or
43 6 7 u-PAR1/1 smooth muscle cells in the presence of
neutralizing u-PA antibodies (50 mg/ml) accumulated in
the wound. Although accumulation of cells into the de-
nuded area could also depend on proliferation, the follow-
ing observations indicate that migration was the principal
(if not the only) mechanism responsible for cell accumula-
tion. Indeed, similar numbers of u-PAR1/1 cells (25 6 4)
and u-PAR2/2 cells (26 6 2) accumulated within 6 h after
scraping, i.e., before the cells had divided (the doubling
time of cultured murine smooth muscle cells was estimated
to be z10–12 h). In addition, g-irradiation of smooth muscle
cells (which blocked proliferation of wild-type and u-PAR2/2
cells by .98% without cytotoxic effects on lactate dehy-
drogenase release) did not affect cellular accumulation. In-
deed, 187 6 13 non–g-irradiated vs. 176 6 19 g-irradiated
wild-type cells (P 5 NS), and 178 6 21 non–g-irradiated
vs. 181 6 18 g-irradiated u-PAR2/2/ cells (P 5 NS) accumu-
lated into the wound within 72 h after wounding. More-
over, proliferation (quantitated by [3H]thymidine incorpora-
tion) of smooth muscle cells during the 72-h migration
period was similar in wild-type cells (7,830 6 1,200 cpm/
105 cells) as in u-PAR2/2 cells (7,740 6 1,000 cpm/105 cells;
Figure 2. Light microscopic analysis of vascular wound healing
and neointima formation after electric injury. All sections were
stained with hematoxylin-eosin. (a) uninjured u-PAR1/1 artery,
revealing the presence of smooth muscle cells in the media. (b–d)
artery from a u-PAR1/1 (b) and a u-PAR2/2 (c) mouse (at loca-
tion 5 as defined in Fig. 1) 3 wk after injury, revealing a similar
neointima in u-PAR2/2 as in u-PAR1/1 arteries. For comparison,
an electrically injured artery from a u-PA2/2 mouse (d), revealing
impaired wound healing and a much smaller neointima is dis-
played (reproduced from reference 9). The arrows indicate the
internal elastic lamina whereas the arrowheads indicate the exter-
nal elastic lamina. Bar, 50 mm.Carmeliet et al. Role of u-PAR in Vascular Wound Healing 237
P 5 NS). Taken together, deficiency of u-PA but not of
u-PAR impairs smooth muscle cell migration under the
present experimental conditions.
Reendothelialization
Electric injury completely denuded the injured segment of
intact endothelium as revealed by Evans blue staining im-
mediately after injury (2.8 6 0.2 mm in six u-PAR1/1 ar-
teries versus 2.9 6 0.3 mm in five u-PAR2/2 arteries). Re-
endothelialization initiated from the uninjured borders
into the necrotic center and was almost complete within 1 wk
after injury in u-PAR1/1 mice (0.7 6 0.2 mm; n 5 7 arter-
ies). u-PAR deficiency did not affect endothelial regrowth
within 7 d after injury (0.8 6 0.4 mm; n 5 5 arteries; P 5 NS).
Expression of a Functional u-PAR by Smooth
Muscle Cells
To exclude that u-PAR gene inactivation failed to affect
smooth muscle cell migration because u-PAR would not
be expressed by wild-type smooth muscle cells, expression
of the u-PAR gene, and protein function by wild-type cells
were analyzed.
In Situ Hybridization. A low level of basal u-PAR mRNA
expression was detectable in uninjured arteries (Fig. 5 a).
Beyond 1 wk after injury, when smooth muscle cells mi-
grate into the necrotic wound, u-PAR mRNA levels were
significantly increased in cells that repopulated the media,
accumulated in the neointima, and infiltrated in the adven-
titia (Fig. 5 c). u-PAR mRNA expression appeared to be
maximal at the leading edge of the cellular migration
front. Only background hybridization was detected using a
control sense probe (Fig. 5, b and d). RT-PCR, followed
by sequencing of cloned RT-PCR amplicons, confirmed
the presence of specific u-PAR mRNA transcripts in wild-
type arteries before and 1–2 wk after injury, as well as in
wild-type cultured smooth muscle cells (not shown). Taken
together, these data suggest that u-PAR is induced in mi-
gratory cells during wound healing, and indicate that the
lack of an effect on neointima formation by u-PAR defi-
ciency is not because of absent u-PAR expression in wild-
type arteries.
Binding of 125I–mu-PA1–48 to Smooth Muscle Cells. To pro-
vide direct proof for the presence of a functional u-PAR,
binding of 125I–mu-PA1–48 to cultured smooth muscle
cells was evaluated. u-PAR1/1 cells incubated with 2 nM
125I–mu-PA1–48 bound 420 6 11 cpm 125I–mu-PA1–48. A 10-
or 100-fold molar excess of unlabeled mu-PA1–48 reduced
binding to 8 6 4 cpm and 0 6 0 cpm, respectively (P ,
0.05; n 5 3). In contrast, a 100-fold molar excess of human
single-chain u-PA was less effective (265 6 21 cpm; P ,
0.05; n 5 3), which is in line with the observations that
u-PA binding to u-PAR is species-specific (26). In con-
trast, u-PAR2/2 cells bound only 10 6 9 cpm when incubated
with 2 nM 125I–mu-PA1–48. Similar binding characteristics
were observed with other murine cell types (fibroblasts and
macrophages) (23).
These quantitative data were extended by in situ autora-
diography to visualize binding of 125I–mu-PA1–48 on the
surface of cultured smooth muscle cells. As can be seen
Figure 3. Morphometric analysis in electrically in-
jured arteries, revealing similar cross-sectional
neointimal area (a), intima to media ratio (b), per-
cent luminal stenosis (c), and neointimal cell counts
(d) in u-PAR2/2 and in u-PAR1/1 mice after electric
injury. The data represent the mean 6 SEM of mea-
surements in 8–14 arteries. u-PAR1/1, wild-type;
u-PAR2/2, u-PAR deficient.
Table I. Proliferation (in Percent) of Medial and Neointimal 
Cells in u-PAR1/1 and u-PAR2/2 Arteries After Electric Injury
Time after injury
Week 1 Week 2 Week 3 Week 4
Neointimal cells
u-PAR1/1 11 6 28  6  25  6  2 0.5 6 0.3
u-PAR2/2 8 6 2 15 6 34  6  1 0.3 6 0.3
Medial cells
u-PAR1/1 29 6 4 15 6 4 12 6 3 0.8 6 0.5
u-PAR2/2 21 6 4 37 6 4* 23 6 10 0.4 6 0.3
Proliferation of medial and neointimal cells was quantified by counting the number of
59-bromo-29-deoxyuridine–positive nuclei on five equally spaced sections per artery
across the injured segment, and were averaged per artery. The values represent the
mean 6 SEM of these averages in groups containing between 8 and 14 arteries. u-PAR1/1,
wild type; u-PAR2/2, u-PAR deficient.
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from the light microscopic analysis, 125I–mu-PA1–48 (2 nM)
bound to u-PAR1/1 cells (Fig. 5 e) but not in the presence
of 100-fold molar excess of unlabeled competitor (Fig. 5 g).
Background binding of 125I–mu-PA1–48 to u-PAR2/2 cells
(Fig. 5 f) was not affected by excess unlabeled competitor
(Fig. 5 h). Electron microscopy confirmed that 125I–mu-PA1–48
was associated with the plasma membrane of u-PAR1/1
cells but not of u-PAR2/2 cells (Fig. 5, i and j).
Taken together, smooth muscle cells express u-PAR dur-
ing wound healing in vivo and in vitro, enabling them to
bind u-PA on their cellular surface with high affinity. In
addition, since binding on u-PAR1/1 cells was completely
inhibited by a 100-fold excess of competitor murine u-PA,
and residual binding of u-PA on u-PAR2/2 cells was mini-
mal, it is unlikely that smooth muscle cells express another
high affinity u-PA–binding receptor.
Pericellular u-PA–mediated Plasmin Proteolysis
A possible explanation for the similar migration rate of
u-PAR2/2 versus u-PAR1/1 cells may relate to the pres-
ence of sufficient pericellular u-PA–mediated plasmin
proteolysis around mutant cells. This was analyzed by
evaluating the presence of u-PA antigen and activity around
u-PAR2/2 cells.
Immunoelectron Microscopy of u-PA in Injured Arteries
In Vivo. The localization of u-PA around migrating cells in
injured arteries in vivo was ultrastructurally examined by
immunogold labeling of u-PA in the injured arteries
within 1 wk after injury i.e., when cell migration is maxi-
mal and u-PA is readily detectable in the injured arteries.
Two antisera (a polyclonal and monoclonal) with similar
labeling characteristics were used, which were previously
shown to specifically detect murine u-PA, as indicated by
the lack of staining in u-PA2/2 arteries, by the colocaliza-
tion of u-PA immunoreactivity with u-PA mRNA hybrid-
ization signals and with in situ zymographic u-PA activity,
by their potential to immunoneutralize u-PA activity in
murine tissue extracts or cell-conditioned media (10), and
by their recognition of purified murine u-PA antigen by
Western blot analysis (not shown).
In u-PAR1/1 cells, u-PA gold particles were detected in
close association with the cell surface, specifically on cell pro-
jections (Fig. 6, a–c, arrows) as well as in the extracellular
matrix (Fig. 6, b and c, arrowheads). In contrast, although
u-PA gold particles were present in secretory granules in-
side u-PAR2/2 cells (presumably indicating biosynthesis of
u-PA) (Fig. 6, d and e, SG), they were predominantly ob-
served in the extracellular matrix in the vicinity of u-PA
producing cells (Fig. 6, d and e, arrowheads). Overall, com-
Figure 4. Topographic analysis of the arterial neointima forma-
tion in u-PAR1/1 and u-PAR2/2 arteries within 1 (a) and 3 (b) wk
after injury. Within 1 wk after injury, neointima formation ini-
tiates from the uninjured borders, whereas within 3 wk after in-
jury, a significant neointima has formed across the entire injured
segment in both u-PAR2/2 and u-PAR1/1 arteries (P 5 NS ver-
sus u-PAR2/2). The data represent the mean 6 SEM of the mor-
phometric measurements in at least seven arteries, determined at
similar relative topographic locations throughout the injured seg-
ment. The number of the relative locations throughout the in-
jured segment refers to those defined in Fig. 1 beneath each sche-
matically represented artery.
Table II. Topographic Pattern of Medial Cell Repopulation
Time after
injury Genotype
Topographic location across injury
Border
(position 1)
Center
(position 5)
Border
(position 10)
1 week u-PAR1/1 53 6 78  6  3* 58 6 5
u-PAR2/2 99 6 12 22 6 8* 94 6 10
3 weeks u-PAR1/1 62 6 7 47 6 6 72 6 5
u-PAR2/2 63 6 8 46 6 11 55 6 13
The data represent the mean 6 SEM of the number of cells in at least seven arteries,
determined at similar relative topographic locations throughout the injured arterial
segment. The topographic locations are indicated on the schematically represented ar-
teries in Fig. 1.
*P , 0.05 versus uninjured border (positions 1 or 10) by analysis of variance with
Bonferroni correction.
Table III. Topographic Pattern of Neointimal
Cell Accumulation
Time after
injury Genotype
Topographic location across injury
Border
(position 1)
Center
(position 5)
Border
(position 10)
1 week u-PAR1/1 124 6 29 47 6 14* 117 6 25
u-PAR2/2 121 6 31 30 6 10* 166 6 23
3 weeks u-PAR1/1 184 6 47 153 6 28 219 6 32
u-PAR2/2 201 6 36 158 6 40 159 6 33
The data represent the mean 6 SEM of the number of neointimal cells in at least
seven arteries, determined at similar relative topographic locations at the uninjured
borders or throughout the injured arterial segment. The topographic positions are indi-
cated on the schematically represented arteries in Fig. 1.
*P , 0.05 versus uninjured border (locations 1 or 10) by analysis of variance with
Bonferroni correction.Carmeliet et al. Role of u-PAR in Vascular Wound Healing 239
parable numbers of u-PA gold particles appeared to be
present in the extracellular matrix around u-PAR2/2 cells
as bound on the surface of, and associated with the extra-
cellular matrix around u-PAR1/1 cells (although a quanti-
tative analysis was not performed). The various compo-
nents of the extracellular matrix were not individually
characterized, but u-PA gold particles were detected on
collagen type I and III fibers, which can be identified be-
cause of their characteristic structural appearance (Fig. 6
b, arrowheads). In addition, u-PA gold particles appeared
scattered throughout the extracellular matrix, which is
known to contain laminin and fibronectin, but were only
rarely detected on elastin fibers (Fig. 6 e, IEL), indicating
that binding occurred preferentially to some but not to all
extracellular matrix components.
Accumulation of u-PA in the Pericellular Milieu.  Because
u-PAR has been involved in internalization of u-PA, defi-
ciency of u-PAR may result in increased extracellular ac-
cumulation of u-PA. Therefore, smooth muscle cells, fi-
broblasts, and macrophages were cultured in vitro and the
amount of u-PA accumulated in their conditioned medium
quantitated by ELISA. As shown in Table IV, slightly
higher amounts of u-PA accumulated around u-PAR2/2
than u-PAR1/1 cells. Quantitation of u-PA by the more
sensitive zymography revealed that u-PA activity levels
(expressed as units/106 cells/48 h) were 1,600 6 70 for
u-PAR1/1 smooth muscle cells and 3,600 6 400 for u-PAR2/2
smooth muscle cells (P , 0.05 vs. wild-type).
125I-Fibrin Degradation and Plasminogen Activation by
Endogenous u-PA. Pericellular plasmin proteolysis by in-
tact u-PAR2/2 cells was evaluated by degradation of 125I-
fibrin. Initial experiments revealed that cultured smooth
muscle cells could not reliably be used for studying degra-
dation of 125I-fibrin since they produced significant amounts
of t-PA, which lysed the underlying fibrin and caused cells
to detach. Therefore, thioglycollate-stimulated peritoneal
macrophages were used because they produce significant
amounts of u-PA but not of t-PA (10). Furthermore, mac-
rophages significantly participate in the repair of the vas-
cular wound after electric injury (14). Plasminogen-depen-
dent degradation of 125I-labeled fibrin after 8 h by u-PAR1/1
and u-PAR2/2 macrophages was 9,500 6 3,500 cpm (n 5
6) and 12,400 6 2,400 cpm (n 5 8), respectively (P 5 NS),
but only 1,000 6 300 cpm (n 5 6) by u-PA2/2 cells (P ,
0.05 vs. wild-type and u-PAR2/2 by analysis of variance).
The latter was not significantly different from the plasmi-
nogen-independent degradation by wild-type cells (600 6
200 cpm; n 5 6), u-PAR2/2 cells (800 6 100 cpm; n 5 9),
or u-PA2/2 cells (500 6 160 cpm; n 5 5). Thus, u-PAR2/2
cells can degrade 125I-labeled fibrin equally well as wild-
Figure 5. Expression of u-PAR. (a–d) In situ hy-
bridization of an uninjured (a and b) or injured (c
and d) wild-type artery within 1 wk after injury (at
locations 1–3 or 8–10 as defined in Fig. 1) with an
antisense (a and c) or sense (b and d) murine u-PAR
probe, revealing a low basal level of u-PAR mRNA
expression in a quiescent artery and significantly
induced u-PAR mRNA levels at the leading front
of cellular migration. The arrows indicate the in-
ternal elastic lamina; the arrowheads indicate the
external elastic lamina. (e–j) Autoradiography
(light microscopy: e–h, or electron microscopy:
i and j) of cultured u-PAR1/1 ( e ,  g, and i) and
u-PAR2/2 (f, h, and j) smooth muscle cells, incu-
bated with 2 nM murine 1–48u-PA alone (e, f, i, and
j) or together with a 100-fold excess of unlabeled
competitor (g and h), revealing significant binding
to u-PAR1/1 but not to u-PAR2/2 smooth muscle
cells. Bar, 25 mm.The Journal of Cell Biology, Volume 140, 1998 240
type cells, whereas u-PA2/2 cells are defective in matrix
degradation.
Plasminogen activation by thioglycollate-stimulated mac-
rophages (quantitated by conversion of the chromogenic
plasmin substrate S2403 and expressed in milliabsorbance
at 405 nm; n 5 3) was threefold lower with u-PAR2/2 cells
(28 6 5) than with u-PAR1/1 cells (95 6 19; P , 0.05)
within 3 h, but comparable with u-PAR2/2 cells (480 6
120) as with u-PAR1/1 cells (590 6 100; P 5 NS) within 7 h,
indicating that plasminogen activation by u-PAR2/2 cells
was only transiently reduced (23). Taken together, the ul-
trastructural, fibrin degradation, and plasminogen activa-
tion data suggest that u-PA is present in the extracellular
matrix around u-PA–producing cells, providing them with
sufficient pericellular plasmin proteolysis to migrate.
Role of t-PA in u-PAR2/2 Arteries
t-PA plays a neglible role in smooth muscle cell migration
Figure 6. Ultrastructural lo-
calization of u-PA in vivo.
Immunogold labeling of
u-PA in u-PAR1/1 (a–c) and
u-PAR2/2 (d and e) arteries,
revealing u-PA bound to the
cell surface (a–c, arrows) on
endothelial cells (EC) or
smooth muscle cells (SMC),
or associated with the extra-
cellular matrix (ECM) (b and
c,  arrowheads) in u-PAR1/1
arteries. Note the presence of
u-PA gold particles on cell
projections (a), and on col-
lagen (CL) fibers in the ex-
tracellular matrix (b). In con-
trast, in u-PAR2/2 arteries,
u-PA gold particles were pre-
dominantly detected in the
pericellular milieu associ-
ated with extracellular ma-
trix components (d and e, ar-
rowheads). Note the paucity
of u-PA gold particles on the
elastin fibers of the internal
elastic lamina (IEL) (e).
Gold particles labeling u-PA
were also found in secretory
granules inside u-PAR2/2
cells (d and e, SG).
Table IV. Accumulation of u-PA Around uPAR1/1
and u-PAR2/2 Cells
u-PA t-PA
Macrophages
u-PAR1/1 3.6 6 0.2 0.04 6 0.02
u-PAR2/2 7.3 6 0.5* 0.10 6 0.01
Smooth muscle cells
u-PAR1/1 <50 40 6 4
u-PAR2/2 55 6 6 78 6 8*
Fibroblasts
u-PAR1/1 26 6 18 50 6 10
u-PAR2/2 47 6 23 43 6 1
The data represent the mean 6 SEM of the measurements (n 5 2 or 3). u-PA and t-PA
concentrations in the conditioned media were measured via ELISA expressed as ng/
106 cells/48 h culture. Thioglycollate-stimulated peritoneal macrophages were freshly
harvested, whereas smooth muscle cells and fibroblasts were cultured.
*P , 0.05 versus wild type by analysis of variance.Carmeliet et al. Role of u-PAR in Vascular Wound Healing 241
in vitro and in vivo (9). To examine whether deficiency of
u-PAR would compensatorily upregulate expression of t-PA,
which could rescue impaired migration of u-PAR2/2 cells,
extracts from uninjured arteries were zymographically an-
alyzed for t-PA activity. u-PAR1/1 arteries contained 1.14 6
0.19 units t-PA (n 5 10), which was not different from
u-PAR2/2 arteries (which contained 1.37 6 0.19 units t-PA
[n 5 8; P 5 NS versus u-PAR1/1]). Thus, it is unlikely that
t-PA plays a more important role in u-PAR2/2 than in
u-PAR1/1 arteries.
Role of u-PAR in Activation of MMPs
Expression of MMPs during Arterial Wound Healing. In a re-
cent study, u-PA–generated plasmin was demonstrated to
activate the proform of several MMPs, including proMMP-9
and proMMP-13 (11). Therefore, the role of u-PAR in
this process was evaluated. Immunostaining revealed ab-
sent expression of MMP-9 and MMP-13 in uninjured con-
trol arteries, but significantly induced expression of MMP-9
and MMP-13 in wild-type arteries within 1 and 2 wk after
injury (e.g., when cells migrate most actively) (Fig. 7).
Since double-labeling studies demonstrated that MMP-9
and MMP-13 are expressed by macrophages (not shown)
and macrophages play a central role in arterial wound
healing in vivo, macrophages were used to study the role
of u-PAR in activation of proMMP-9 and proMMP-13.
Activation of proMMPs. To study activation of proMMPs
by plasmin (which occurs extracellularly), and to avoid
possible contamination by artefactual activation of intra-
cellularly stored proMMPs upon tissue extraction, thiogly-
collate-stimulated peritoneal macrophages were cultured
in the absence or presence of plasminogen; and activation
of proMMP-9 and proMMP-13 assayed by gelatin zymog-
raphy of their conditioned medium (MMP-9), or by auto-
radiography of conditioned medium from metabolically
labeled macrophages after immunoprecipitation (MMP-9,
MMP-13). As shown in Fig. 8, conditioned medium from
wild-type  and u-PAR2/2 macrophages, cultured without
plasminogen,  contained the inactive form of MMP-9 (z92
kD) and MMP-13 (z57 kD). When the macrophages were,
however, cultured in the presence of plasminogen, their
conditioned medium contained in addition the active cleav-
age product of MMP-9 (z82 kD) and MMP-13 (z45-kD
doublet and an intermediately processed higher molecular
mass form). In contrast, medium from u-PA2/2 macro-
phages only contained the inactive MMP-9 and MMP-13
zymogens, irrespective of the presence of plasminogen in
the culture medium. Taken together, these results indicate
that u-PAR2/2 cells produce sufficient pericellular u-PA–
generated plasmin to activate proMMPs.
Discussion
Receptor-independent Role of u-PA in Smooth Muscle 
Cell Migration
It has been proposed that binding of u-PA to u-PAR is re-
quired for its proteolytic activity, since this might acceler-
ate plasminogen activation, concentrate u-PA onto the cell
surface, and possibly protect u-PA from inactivation by
PAI-1 (2, 4, 27, 57). We previously demonstrated that
smooth muscle cells produce and require u-PA for migra-
tion and formation of a neointima. Since smooth muscle
cell migration was impaired by u-PA deficiency (9) as well
as by plasminogen deficiency (13), the biological role of
u-PA during vascular wound healing appears to depend
primarily on generation of plasmin. The latter mediates de-
gradation of the extracellular matrix components either
directly or indirectly via activation of zymogen MMPs. In
the present study, evidence is provided for a receptor-
independent role of u-PA in smooth muscle cell migration.
Indeed, the observations that u-PAR deficiency did not af-
fect the initiation, formation, and progression of the neo-
intima from the uninjured borders into the necrotic center
of the wound, and that migration of smooth muscle cells in
vivo and in vitro was unaffected by u-PAR deficiency, in-
Figure 7. Immunostaining of
MMP-9 and MMP-13. MMP-9
(a and b) and MMP-13 (c and
d) immunoreactivity were ab-
sent in uninjured wild-type ar-
teries (a and c), but were
markedly upregulated through-
out the entire vessel wall after
injury (b and d). The arrows in-
dicate the internal elastic lamina
whereas  the arrowheads indi-
cate the external elastic lamina.The Journal of Cell Biology, Volume 140, 1998 242
dicates that u-PAR is not essential for u-PA–dependent
plasmin proteolysis during smooth muscle cell migration
(see also Fig. 1 for schematic representation). The present
study does, however, not exclude that u-PA may also af-
fect cellular migration via nonproteolytic mechanisms, e.g.,
via binding of the NH2-terminal fragment of u-PA to u-PAR
with subsequent signaling (1, 20, 28, 43, 44, 46, 58). Eluci-
dation of such a mechanism in vivo may, however, have to
await the generation of transgenic mice selectively ex-
pressing mutant u-PA that is catalytically inactive but still
able to bind u-PAR.
Lack of an Effect of u-PAR Is Not Because
of Lack of u-PAR Expression by Wild-Type Cells or to 
Compensatory t-PA Overexpression
There are several possibilities why loss of u-PAR gene
function might not result in impairment of neointima for-
mation, as observed in u-PA–deficient arteries. One rea-
son is that u-PAR may not be expressed by smooth muscle
cells during vascular wound healing. However, the obser-
vations that smooth muscle cells express u-PAR mRNA in
vitro and in vivo, and that they possess a functional u-PAR,
able to bind u-PA with similar affinity as observed for
other cell types (41, 45), excludes this possibility and makes
it unlikely that u-PAR has modified binding properties. In
addition, there was no evidence for another u-PA–binding
receptor with a similar high affinity on smooth muscle cells,
consistent with previous observations (5, 23).
A second possible reason is that compensatorily upregu-
lated levels of t-PA in u-PAR2/2 arteries could rescue mi-
gration of u-PAR2/2 smooth muscle cells. However, t-PA
activity levels were similar in wild-type and in mutant ar-
teries. In addition, t-PA plays a neglible role in smooth
muscle cell migration in vitro and in vivo (9). Furthermore, a
compensatory upregulation of t-PA expression in u-PA2/2
or u-PAR2/2 mice was never observed. In fact, it might
have been expected that deficiency of u-PA rather than of
u-PAR would compensatorily increase t-PA, since total
plasminogen activator activity is lower in u-PA2/2 than in
u-PAR2/2 mice. Nevertheless, t-PA activity was not com-
pensatorily increased in u-PA2/2 mice (9).
Pericellular Localization of u-PA and
u-PA–mediated Plasmin and MMP Proteolysis
Around u-PAR2/2 Cells
Another explanation for the negligible role of u-PAR in
smooth muscle cell migration is that u-PA would not need
to be bound to u-PAR but could be present in the pericel-
lular environment to provide sufficient u-PA–mediated
plasmin proteolysis to u-PAR2/2 cells. This hypothesis
is substantiated by our findings that u-PA accumulates in
slightly increased amounts in the conditioned medium
around u-PAR2/2 cells in vitro, that u-PA is detected ul-
trastructurally in the surrounding extracellular matrix
in u-PAR2/2 arteries in vivo, and that pericellular plas-
min proteolysis (evidenced by 125I-fibrin degradation)
or matrix metalloproteinase proteolysis (evidenced by
proMMP-9 and proMMP-13 activation) by u-PAR2/2 cells
is similar to that produced by u-PAR1/1 cells. Such a mech-
anism is further supported by previous observations that
membrane-anchored u-PA (29), or soluble u-PA (60, 65),
is biologically active.
The role of u-PAR in plasminogen activation remains
controversial. u-PAR on whole cells accelerates plasmino-
gen activation by u-PA within a period of ,1 h, as the ad-
dition of human U937 cells to mixtures of plasminogen
and u-PA resulted in a significant increase in plasmin gen-
eration (25). Since nM concentrations of u-PA (e.g., within
the range of the Kd for u-PA-binding to u-PAR) were
added to cells in suspension, binding of u-PA to u-PAR
(and not to other binding sites, such as those in the extra-
cellular matrix) occurred. This increase was abolished by
agents blocking the cellular binding site of either u-PA or
plasminogen, indicating the dependence of the accelerat-
ing effect on the presence of both types of binding sites
(4). In contrast, acceleration of plasminogen activation
was not observed in a similar assay using murine u-PA–defi-
cient endothelioma cells, in spite of the presence of func-
tional u-PAR on these cells (32). These conflicting results
might relate to differences between the human and murine
system, or to the characteristics of the cell lines used.
These assays may, however, not reliably reflect the in
vivo situation in which not only cellular u-PAR but also al-
ternative u-PA–binding sites in the pericellular milieu may
contribute to the biological role of u-PA. Indeed, migrat-
ing cells in the electrically injured arteries produce .100-
fold increased u-PA levels during prolonged periods (days
to weeks). Consequently, the pericellular u-PA levels
might raise above those needed to saturate binding to
u-PAR and allow its binding to other sites in the pericellu-
lar milieu (cf the ultrastructural analysis in vivo). Consis-
tent with such a hypothesis, adherent u-PAR–deficient
macrophages generated less plasmin upon short incuba-
tion (acceleration of plasminogen activation by u-PAR)
(4), whereas they generated comparable plasmin levels to
wild-type cells upon prolonged incubation (e.g., .4 h, a
time period sufficient for accumulation of u-PA in the
Figure 8. Plasmin(ogen) de-
pendent activation of matrix
metalloproteinases. (a) gela-
tin zymography after MMP-9
immunoprecipitation; (b and
c) autoradiograph from met-
abolically labeled macro-
phage-conditioned medium
after MMP-9 (b) or MMP-13
(c) immunoprecipitation. In
the  absence of plasminogen
(2Plg), only the zymogen
proMMP-9 (z92 kD, a and
b) and proMMP-13 (z57 kD,
c) are present in the condi-
tioned medium from mac-
rophages of all genotypes. In
the presence of plasminogen
(1Plg; 10 mg/ml), these pro-
forms are processed to the
active MMP-9 (z82 kD) and
MMP-13 (z45-kD doublet
and partially processed
forms) by wild-type (WT)
and u-PAR–deficient (u-PAR2/2) macrophages but not by u-PA–
deficient (u-PA2/2) macrophages.Carmeliet et al. Role of u-PAR in Vascular Wound Healing 243
pericellular milieu and supernatant) (23). Similarly, the
lack of effect of u-PAR deficiency on 125I-fibrin degrada-
tion or cell migration, both processes requiring prolonged
assay times (hours to days), might be explained by the
presence of sufficient u-PA in the pericellular milieu.
Taken together, although u-PAR may accelerate plasmin
generation over a period of minutes to hours, this kinetic
advantage may be less significant for slow processes (re-
quiring days to weeks to develop) than the total amount of
plasmin generated.
To what components in the extracellular matrix u-PA
binds, remains to be determined, but previous studies have
demonstrated that u-PA can bind fibrin, heparin, laminin,
thrombospondin, and fibronectin (17, 36, 37, 39, 48, 51, 52,
54, 55). Furthermore, since plasminogen also binds some
of the above-mentioned matrix components, u-PA (through
binding with plasminogen) can be closely associated with
the extracellular matrix. The present experiments do not
exclude that u-PA may bind to another low affinity cellu-
lar or soluble receptor, although no evidence for such a
molecule has been provided to date.
Cellular Proliferation
Cellular proliferation was not affected by deficiency of
u-PAR, except for a transient increase of neointimal cell
proliferation within 2 wk after injury. It is unclear why de-
ficiency of u-PAR would induce cell proliferation. u-PAR
has been implicated in cell growth and other cellular pro-
cesses via mediating intracellular signaling (20, 43), but to
date, an inhibitory role for u-PAR in cell growth has not
been documented. Smooth muscle cells dedifferentiate
when they proliferate and migrate into the intima (as evi-
denced by their reduced a-actin expression) (14) but redif-
ferentiate after their arrival in the intima (increased a-actin
expression) (14). Whether u-PAR deficiency would pre-
vent/delay smooth muscle cell differentiation, as in mac-
rophages (44), remains to be determined.
Role of u-PAR in Endothelial Cell Regeneration
Endothelial cell regrowth was not affected by u-PAR defi-
ciency. However, reendothelialization was also not af-
fected by deficiency of u-PA, t-PA, PAI-1, or plasminogen
(9, 13), indicating that regenerating endothelial cells may
not require plasmin to migrate alongside the denuded in-
ternal elastic lamina. This is somewhat surprising in view of
the induced expression of plasminogen activators in regen-
erating endothelium in vivo and in vitro after injury (45,
57). The plasminogen system plays, however, a more es-
sential role during pathological blood vessel formation when
endothelial cells migrate through anatomic barriers (47).
Requirement of u-PAR in Other Biological Processes
Previous studies have demonstrated that inhibition of
u-PAR gene function, either by antisense to u-PAR or by
inhibition of the u-PA/u-PAR interaction, suppresses pri-
mary tumor growth, tumor-associated neovascularization,
and metastasis (19, 38, 42, 66). Apparently, u-PAR plays
a more essential role in these processes than during arte-
rial neointima formation. This may, however, be related to
differences in the level or the temporospatial pattern of
u-PAR expression, or the contextual requirement for
u-PA–mediated plasmin proteolysis. In addition, u-PAR is a
multifunctional receptor involved in vitro in pericellular
proteolysis, cell proliferation, differentiation, and adhe-
sion, and the contribution of each of these mechanisms
may determine the requirement of u-PAR in different bio-
logical processes. Unresolved issues include whether u-PAR
may have other biological functions during vascular wound
healing, for example on cellular differentiation or adhesion,
which were not revealed by our analysis, or whether recep-
tor binding is essential during other u-PA–dependent bio-
logical processes in vivo. The growing list of phenotypes
resulting from loss of u-PA gene function in gene-inacti-
vated mice, which include fibrin deposition (10), impaired
myocardial healing (unpublished data), and atheroscle-
rotic aneurysm formation (11) may aid in addressing this
issue in the future. In particular, since u-PAR has been im-
plicated in cancer, appropriate models in the gene-inacti-
vated mice may be useful to unravel its possible role in this
process.
In conclusion, deficiency of u-PAR does not affect arte-
rial neointima formation, most likely because accumulation
of u-PA in the extracellular environment compensates for
binding on its cellular receptor. These data suggest that
antifibrinolytic therapy for arterial stenosis should be tar-
geted at inhibiting u-PA activity rather than its binding on
u-PAR.
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